Mitsubishi UFJ Asset Management Co. Ltd. Buys Shares of 50,907 Hims & Hers Health, Inc. (NYSE:HIMS)

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 50,907 shares of the company's stock, valued at approximately $1,356,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its stake in shares of Hims & Hers Health by 15.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company's stock worth $30,714,000 after acquiring an additional 218,566 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in Hims & Hers Health by 5.8% in the third quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company's stock valued at $622,000 after purchasing an additional 1,864 shares in the last quarter. Centiva Capital LP increased its stake in Hims & Hers Health by 13.1% in the 3rd quarter. Centiva Capital LP now owns 81,811 shares of the company's stock valued at $1,507,000 after buying an additional 9,468 shares during the last quarter. HighTower Advisors LLC bought a new stake in Hims & Hers Health during the 3rd quarter worth about $207,000. Finally, Quarry LP boosted its stake in shares of Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company's stock worth $113,000 after buying an additional 2,913 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Bank of America lifted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research report on Tuesday, March 18th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Wednesday, April 2nd. Truist Financial raised their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a research note on Wednesday, February 26th. Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Needham & Company LLC increased their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average price target of $37.31.

Remove Ads

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total value of $63,402.34. Following the completion of the sale, the insider now owns 8,007 shares of the company's stock, valued at $230,441.46. The trade was a 21.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $24.44, for a total transaction of $283,039.64. Following the transaction, the chief financial officer now directly owns 118,077 shares in the company, valued at $2,885,801.88. This represents a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 809,806 shares of company stock worth $30,923,658. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Trading Up 6.6 %

HIMS stock traded up $1.72 during mid-day trading on Monday, hitting $27.71. 26,460,112 shares of the company were exchanged, compared to its average volume of 14,777,841. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The stock has a market capitalization of $6.16 billion, a PE ratio of 62.97 and a beta of 1.65. The business has a 50 day simple moving average of $39.76 and a 200-day simple moving average of $30.11.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.